{"id":9121,"date":"2025-07-14T06:06:03","date_gmt":"2025-07-14T11:06:03","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=9121"},"modified":"2025-07-23T18:39:41","modified_gmt":"2025-07-23T23:39:41","slug":"nanoscope-therapeutics-initiates-rolling-submission-of-biologics-license-application-to-fda-for-mco-010-the-first-gene-agnostic-therapy-to-treat-retinitis-pigmentosa","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/ar\/2025\/07\/14\/nanoscope-therapeutics-initiates-rolling-submission-of-biologics-license-application-to-fda-for-mco-010-the-first-gene-agnostic-therapy-to-treat-retinitis-pigmentosa\/","title":{"rendered":"\u0628\u062f\u0623\u062a \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633 \u0628\u062a\u0642\u062f\u064a\u0645 \u0637\u0644\u0628 \u062a\u0631\u062e\u064a\u0635 \u0627\u0644\u0645\u0646\u062a\u062c\u0627\u062a \u0627\u0644\u0628\u064a\u0648\u0644\u0648\u062c\u064a\u0629 \u0625\u0644\u0649 \u0625\u062f\u0627\u0631\u0629 \u0627\u0644\u063a\u0630\u0627\u0621 \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a\u0629 (FDA) \u0628\u0634\u0643\u0644 \u062a\u062f\u0631\u064a\u062c\u064a \u0644\u0639\u0644\u0627\u062c MCO-010\u060c \u0648\u0647\u0648 \u0623\u0648\u0644 \u0639\u0644\u0627\u062c \u063a\u064a\u0631 \u0645\u0631\u062a\u0628\u0637 \u0628\u0627\u0644\u062c\u064a\u0646\u0627\u062a \u0644\u0639\u0644\u0627\u062c \u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a."},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"9121\" class=\"elementor elementor-9121\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-6d5ad04f elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"6d5ad04f\" data-element_type=\"section\" data-e-type=\"section\">\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-5bf9bdef\" data-id=\"5bf9bdef\" data-element_type=\"column\" data-e-type=\"column\">\r\n\r\n\t\t\t\t\r\n\t\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-e3a8c93 elementor-widget elementor-widget-text-editor\" data-id=\"e3a8c93\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul><li><h3><em>\u062a\u062e\u0636\u0639 \u0627\u0644\u0648\u062d\u062f\u0627\u062a \u0627\u0644\u0623\u0648\u0644\u0649 \u0645\u0646 \u0637\u0644\u0628 \u062a\u0631\u062e\u064a\u0635 \u0627\u0644\u0645\u0646\u062a\u062c \u0627\u0644\u0628\u064a\u0648\u0644\u0648\u062c\u064a \u0627\u0644\u0645\u0642\u062f\u0645 \u0625\u0644\u0649 \u0625\u062f\u0627\u0631\u0629 \u0627\u0644\u063a\u0630\u0627\u0621 \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a\u0629 \u0644\u0644\u0645\u0631\u0627\u062c\u0639\u0629 \u0627\u0644\u0645\u0633\u062a\u0645\u0631\u0629\u060c \u0648\u0645\u0646 \u0627\u0644\u0645\u062a\u0648\u0642\u0639 \u062a\u0642\u062f\u064a\u0645 \u0627\u0644\u0637\u0644\u0628 \u0627\u0644\u0643\u0627\u0645\u0644 \u0641\u064a \u0623\u0648\u0627\u0626\u0644 \u0639\u0627\u0645 2026.<\/em><\/h3><\/li><li><h3><em>\u064a\u064f\u0639\u062f\u0651 \u062f\u0648\u0627\u0621 MCO-010 BLA \u0644\u0639\u0644\u0627\u062c \u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a \u0645\u0624\u0647\u0644\u0627\u064b \u0644\u0644\u0645\u0631\u0627\u062c\u0639\u0629 \u0630\u0627\u062a \u0627\u0644\u0623\u0648\u0644\u0648\u064a\u0629 \u0628\u0646\u0627\u0621\u064b \u0639\u0644\u0649 \u062a\u0635\u0646\u064a\u0641 \u0627\u0644\u0645\u0633\u0627\u0631 \u0627\u0644\u0633\u0631\u064a\u0639.<\/em><\/h3><\/li><li><h3><em>\u0641\u064a \u062d\u0627\u0644 \u0627\u0644\u0645\u0648\u0627\u0641\u0642\u0629 \u0639\u0644\u064a\u0647\u060c \u064a\u0645\u062a\u0644\u0643 \u0639\u0642\u0627\u0631 MCO-010 \u0627\u0644\u0642\u062f\u0631\u0629 \u0639\u0644\u0649 \u0623\u0646 \u064a\u0635\u0628\u062d \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0642\u064a\u0627\u0633\u064a \u0644\u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a\u060c \u062d\u064a\u062b \u064a\u064f\u0639\u0637\u0649 \u0639\u0646 \u0637\u0631\u064a\u0642 \u062d\u0642\u0646\u0629 \u0648\u0627\u062d\u062f\u0629 \u062f\u0627\u062e\u0644 \u0627\u0644\u062c\u0633\u0645 \u0627\u0644\u0632\u062c\u0627\u062c\u064a \u0641\u064a \u0627\u0644\u0639\u064a\u0627\u062f\u0629\u060c \u0645\u0639 \u0627\u0644\u0642\u062f\u0631\u0629 \u0639\u0644\u0649 \u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631 \u0644\u062f\u0649 \u0627\u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u0630\u064a\u0646 \u064a\u0639\u0627\u0646\u0648\u0646 \u0645\u0646 \u0641\u0642\u062f\u0627\u0646 \u0634\u062f\u064a\u062f \u0644\u0644\u0628\u0635\u0631 \u0628\u063a\u0636 \u0627\u0644\u0646\u0638\u0631 \u0639\u0646 \u0627\u0644\u0637\u0641\u0631\u0629 \u0627\u0644\u062c\u064a\u0646\u064a\u0629 \u0627\u0644\u0643\u0627\u0645\u0646\u0629 \u0644\u062f\u064a\u0647\u0645.<\/em><\/h3><\/li><\/ul><div class=\"col-sm-4 col-xs-12 col-vcenter\"><div class=\"image logo logo-wrapper\" data-src=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=publish\" data-asset-type=\"photo\" data-asset-label=\"Logo\" data-download-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg\" data-tweet-text=\"Nanoscope Therapeutics Logo (PRNewsfoto\/Nanoscope Therapeutics)\" data-pinterest-text=\"Nanoscope Therapeutics Logo (PRNewsfoto\/Nanoscope Therapeutics)\" data-linkedin-text=\"Nanoscope Therapeutics Logo (PRNewsfoto\/Nanoscope Therapeutics)\" data-facebook-share-text=\"Nanoscope Therapeutics Logo (PRNewsfoto\/Nanoscope Therapeutics)\" data-twitter-share-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=twitter\" data-facebook-share-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=facebook\" data-pinterest-share-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=publish\" data-linkedin-share-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=linkedin\"><p><strong>\u062f\u0627\u0644\u0627\u0633\u060c \u062a\u0643\u0633\u0627\u0633\u060c 14 \u064a\u0648\u0644\u064a\u0648 2025<\/strong>\u00a0-\u00a0<a href=\"https:\/\/nanostherapeutics.com\/ar\/\"><strong>\u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633 \u0627\u0644\u0645\u062d\u062f\u0648\u062f\u0629\u060c,<\/strong><\/a> \u0623\u0639\u0644\u0646\u062a \u0634\u0631\u0643\u0629 \u0644\u0644\u062a\u0643\u0646\u0648\u0644\u0648\u062c\u064a\u0627 \u0627\u0644\u062d\u064a\u0648\u064a\u0629 \u0645\u0644\u062a\u0632\u0645\u0629 \u0628\u062a\u0637\u0648\u064a\u0631 \u0648\u062a\u0633\u0648\u064a\u0642 \u0639\u0644\u0627\u062c\u0627\u062a \u062c\u062f\u064a\u062f\u0629 \u063a\u064a\u0631 \u0645\u0631\u062a\u0628\u0637\u0629 \u0628\u0627\u0644\u062c\u064a\u0646\u0627\u062a \u0644\u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u0630\u064a\u0646 \u064a\u0639\u0627\u0646\u0648\u0646 \u0645\u0646 \u0641\u0642\u062f\u0627\u0646 \u0634\u062f\u064a\u062f \u0641\u064a \u0627\u0644\u0628\u0635\u0631 \u0628\u0633\u0628\u0628 \u0623\u0645\u0631\u0627\u0636 \u062a\u0646\u0643\u0633 \u0627\u0644\u0634\u0628\u0643\u064a\u0629\u060c \u0627\u0644\u064a\u0648\u0645 \u0639\u0646 \u0628\u062f\u0621 \u062a\u0642\u062f\u064a\u0645 \u0637\u0644\u0628 \u062a\u0631\u062e\u064a\u0635 \u0628\u064a\u0648\u0644\u0648\u062c\u064a (BLA) \u0625\u0644\u0649 \u0625\u062f\u0627\u0631\u0629 \u0627\u0644\u063a\u0630\u0627\u0621 \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a\u0629 (FDA) \u0644\u0639\u0644\u0627\u062c\u0647\u0627 \u0627\u0644\u062a\u062c\u0631\u064a\u0628\u064a \u0627\u0644\u0631\u0627\u0626\u062f\u060c MCO-010\u060c \u0644\u0639\u0644\u0627\u062c \u0641\u0642\u062f\u0627\u0646 \u0627\u0644\u0628\u0635\u0631 \u0627\u0644\u0634\u062f\u064a\u062f \u0627\u0644\u0646\u0627\u062a\u062c \u0639\u0646 \u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a (RP).<\/p><p>\u064a\u0645\u062b\u0644 \u0647\u0630\u0627 \u0625\u0646\u062c\u0627\u0632\u0627\u064b \u062a\u0646\u0638\u064a\u0645\u064a\u0627\u064b \u0647\u0627\u0645\u0627\u064b \u062d\u064a\u062b \u0623\u0646 <strong>\u0623\u0648\u0644 \u0637\u0644\u0628 \u062a\u0631\u062e\u064a\u0635 \u0628\u064a\u0648\u0644\u0648\u062c\u064a (BLA) \u0645\u0642\u062f\u0645 \u0644\u062c\u064a\u0646 \u063a\u064a\u0631 \u0645\u062d\u062f\u062f<\/strong><strong> \u062c\u064a\u0646<\/strong><strong> \u0645\u064f\u0639\u064e\u0627\u0644\u064e\u062c\u064e\u0629<\/strong><strong> \u0644\u0639\u0644\u0627\u062c \u0623\u0645\u0631\u0627\u0636 \u0627\u0644\u0634\u0628\u0643\u064a\u0629<\/strong>. \u0625\u0646 \u0643\u0648\u0646 MCO-010 \u063a\u064a\u0631 \u0645\u0631\u062a\u0628\u0637 \u0628\u062c\u064a\u0646 \u0645\u0639\u064a\u0646 \u064a\u0639\u0646\u064a \u0623\u0646\u0647 \u0645\u0635\u0645\u0645 \u0644\u0645\u0639\u0627\u0644\u062c\u0629 \u0627\u0644\u062a\u0646\u0648\u0639 \u0627\u0644\u062c\u064a\u0646\u064a \u0627\u0644\u0648\u0627\u0633\u0639 \u0644\u0645\u0631\u0636 \u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a - \u0648\u0647\u0648 \u062d\u0627\u0644\u0629 \u0645\u0631\u062a\u0628\u0637\u0629 \u0628\u0623\u0643\u062b\u0631 \u0645\u0646 100 \u062c\u064a\u0646 \u0645\u0639\u0631\u0648\u0641 \u0648\u0623\u0643\u062b\u0631 \u0645\u0646 1000 \u0637\u0641\u0631\u0629 \u0645\u062e\u062a\u0644\u0641\u0629 -<strong>\u0628\u063a\u0636 \u0627\u0644\u0646\u0638\u0631 \u0639\u0646 \u0627\u0644\u0637\u0641\u0631\u0629 \u0627\u0644\u0623\u0633\u0627\u0633\u064a\u0629<\/strong>.<\/p><p>\u0645\u0646\u062d\u062a \u0625\u062f\u0627\u0631\u0629 \u0627\u0644\u063a\u0630\u0627\u0621 \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a\u0629 \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u0645\u0631\u0627\u062c\u0639\u0629 \u0645\u0633\u062a\u0645\u0631\u0629 \u0644\u0637\u0644\u0628 \u062a\u0631\u062e\u064a\u0635 \u0627\u0644\u0645\u0646\u062a\u062c \u0627\u0644\u0628\u064a\u0648\u0644\u0648\u062c\u064a \u0627\u0644\u062e\u0627\u0635 \u0628\u0647\u0627\u060c \u062d\u064a\u062b \u062a\u0645 \u0628\u0627\u0644\u0641\u0639\u0644 \u062a\u0642\u062f\u064a\u0645 \u0627\u0644\u0648\u062d\u062f\u0627\u062a \u0627\u0644\u0623\u0648\u0644\u0649 \u0648\u0645\u0646 \u0627\u0644\u0645\u062a\u0648\u0642\u0639 \u0627\u0644\u0627\u0646\u062a\u0647\u0627\u0621 \u0645\u0646 \u062a\u0642\u062f\u064a\u0645 \u0637\u0644\u0628 \u062a\u0631\u062e\u064a\u0635 \u0627\u0644\u0645\u0646\u062a\u062c \u0627\u0644\u0628\u064a\u0648\u0644\u0648\u062c\u064a \u0628\u0627\u0644\u0643\u0627\u0645\u0644 \u0641\u064a \u0623\u0648\u0627\u0626\u0644 \u0639\u0627\u0645 2026. \u0627\u0644\u0637\u0644\u0628 \u0645\u0624\u0647\u0644 \u0644\u0644\u0645\u0631\u0627\u062c\u0639\u0629 \u0630\u0627\u062a \u0627\u0644\u0623\u0648\u0644\u0648\u064a\u0629 \u0628\u0645\u0648\u062c\u0628 \u062a\u0635\u0646\u064a\u0641 \u0627\u0644\u0645\u0633\u0627\u0631 \u0627\u0644\u0633\u0631\u064a\u0639 \u0644\u0644\u0628\u0631\u0646\u0627\u0645\u062c.<\/p><p><strong>\u0641\u064a \u062d\u0627\u0644 \u0627\u0644\u0645\u0648\u0627\u0641\u0642\u0629 \u0639\u0644\u064a\u0647\u060c \u0633\u064a\u0643\u0648\u0646 MCO-010 \u0623\u0648\u0644 \u0639\u0644\u0627\u062c \u063a\u064a\u0631 \u0645\u0631\u062a\u0628\u0637 \u0628\u0627\u0644\u062c\u064a\u0646\u0627\u062a \u0644\u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631 \u0644\u062f\u0649 \u0645\u0631\u0636\u0649 \u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a \u0627\u0644\u0645\u0643\u0641\u0648\u0641\u064a\u0646 \u0642\u0627\u0646\u0648\u0646\u064a\u064b\u0627<\/strong>, \u0645\u0645\u0627 \u0642\u062f \u064a\u0648\u0641\u0631 \u0641\u0631\u0635\u0629 \u0633\u0648\u0642\u064a\u0629 \u0643\u0628\u064a\u0631\u0629\u060c \u0648\u0627\u0644\u0623\u0647\u0645 \u0645\u0646 \u0630\u0644\u0643\u060c \u0648\u0636\u0639 \u0645\u0639\u064a\u0627\u0631 \u0627\u0644\u0631\u0639\u0627\u064a\u0629 \u0644\u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u0630\u064a\u0646 \u064a\u0639\u0627\u0646\u0648\u0646 \u0645\u0646 \u0636\u0639\u0641 \u0627\u0644\u0628\u0635\u0631 \u0628\u0633\u0628\u0628 \u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a.<\/p><p>\u201c&quot;\u0644\u0644\u0645\u0631\u0629 \u0627\u0644\u0623\u0648\u0644\u0649\u060c \u0642\u062f \u062a\u062a\u0627\u062d \u0644\u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u0630\u064a\u0646 \u064a\u064f\u0639\u062a\u0628\u0631\u0648\u0646 \u0641\u064a \u0637\u0631\u064a\u0642\u0647\u0645 \u0625\u0644\u0649 \u0641\u0642\u062f\u0627\u0646 \u0627\u0644\u0628\u0635\u0631 \u0627\u0644\u062f\u0627\u0626\u0645 \u0641\u0631\u0635\u0629 \u0644\u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0628\u0635\u0631\u0647\u0645&quot;\u060c\u00a0<a href=\"https:\/\/nanostherapeutics.com\/ar\/who-we-are\/sulagna-bhattcharya\/\">\u0633\u0648\u0644\u0627\u062c\u0646\u0627 \u0628\u0647\u0627\u062a\u0627\u0634\u0627\u0631\u064a\u0627\u060c \u0627\u0644\u0631\u0626\u064a\u0633\u0629 \u0627\u0644\u062a\u0646\u0641\u064a\u0630\u064a\u0629 \u0648\u0627\u0644\u0645\u0624\u0633\u0633\u0629 \u0627\u0644\u0645\u0634\u0627\u0631\u0643\u0629 \u0644\u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628<\/a>. &quot;\u0646\u062d\u0646 \u0645\u0645\u062a\u0646\u0648\u0646 \u0644\u0644\u063a\u0627\u064a\u0629 \u0644\u0625\u062f\u0627\u0631\u0629 \u0627\u0644\u063a\u0630\u0627\u0621 \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0644\u062a\u0648\u062c\u064a\u0647\u0627\u062a\u0647\u0627\u060c \u0625\u0630 \u0646\u0628\u0642\u0649 \u062b\u0627\u0628\u062a\u064a\u0646 \u0641\u064a \u0645\u0647\u0645\u062a\u0646\u0627 \u0644\u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631 \u0648\u0625\u0639\u0627\u062f\u0629 \u0627\u0644\u0646\u0648\u0631 \u0625\u0644\u0649 \u062d\u064a\u0627\u0629 \u0623\u0648\u0644\u0626\u0643 \u0627\u0644\u0630\u064a\u0646 \u064a\u0639\u064a\u0634\u0648\u0646 \u0641\u064a \u0627\u0644\u0638\u0644\u0627\u0645.&quot;\u201c<\/p><p>\u064a\u064f\u0639\u0637\u0649 MCO-010\u060c \u0648\u0647\u0648 \u0623\u0648\u0628\u0633\u064a\u0646 \u0645\u062a\u0639\u062f\u062f \u0627\u0644\u062e\u0635\u0627\u0626\u0635 (MCO) \u062e\u0627\u0635 \u0628\u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628\u060c \u0639\u0646 \u0637\u0631\u064a\u0642 \u062d\u0642\u0646\u0629 \u0648\u0627\u062d\u062f\u0629 \u062f\u0627\u062e\u0644 \u0627\u0644\u062c\u0633\u0645 \u0627\u0644\u0632\u062c\u0627\u062c\u064a \u0644\u0644\u0639\u064a\u0646 \u0641\u064a \u0627\u0644\u0639\u064a\u0627\u062f\u0629. \u0628\u0639\u062f \u0627\u0644\u062d\u0642\u0646\u060c \u064a\u064f\u0641\u0639\u0651\u0644 MCO-010 \u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u062b\u0646\u0627\u0626\u064a\u0629 \u0627\u0644\u0642\u0637\u0628 \u0639\u0627\u0644\u064a\u0629 \u0627\u0644\u0643\u062b\u0627\u0641\u0629 \u0644\u062a\u0635\u0628\u062d \u062d\u0633\u0627\u0633\u0629 \u0644\u0644\u0636\u0648\u0621\u060c \u0645\u0633\u062a\u0641\u064a\u062f\u064b\u0627 \u0645\u0646 \u0627\u0644\u062f\u0648\u0627\u0626\u0631 \u0627\u0644\u0628\u0635\u0631\u064a\u0629 \u0627\u0644\u0645\u062a\u0628\u0642\u064a\u0629 \u0628\u0639\u062f \u0645\u0648\u062a \u0627\u0644\u062e\u0644\u0627\u064a\u0627 \u0627\u0644\u0645\u0633\u062a\u0642\u0628\u0644\u0629 \u0644\u0644\u0636\u0648\u0621. \u0635\u064f\u0645\u0645 MCO-010 \u0644\u064a\u0642\u062f\u0645 \u0646\u0647\u062c\u064b\u0627 \u0641\u0631\u064a\u062f\u064b\u0627\u060c \u0625\u0630 \u0644\u0627 \u064a\u062a\u0637\u0644\u0628 \u0627\u062e\u062a\u0628\u0627\u0631\u0627\u062a \u062c\u064a\u0646\u064a\u0629 \u0623\u0648 \u062a\u062f\u062e\u0644\u064b\u0627 \u062c\u0631\u0627\u062d\u064a\u064b\u0627 \u0623\u0648 \u062c\u0631\u0639\u0627\u062a \u0645\u062a\u0643\u0631\u0631\u0629\u060c \u0645\u0645\u0627 \u064a\u062c\u0639\u0644\u0647 \u0645\u0646\u0627\u0633\u0628\u064b\u0627 \u0644\u0634\u0631\u064a\u062d\u0629 \u0648\u0627\u0633\u0639\u0629 \u0645\u0646 \u0645\u0631\u0636\u0649 \u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a\u060c \u0643\u0645\u0627 \u0623\u0646\u0647 \u064a\u0646\u0633\u062c\u0645 \u0645\u0639 \u0625\u062c\u0631\u0627\u0621\u0627\u062a \u0627\u0644\u0639\u0645\u0644 \u0627\u0644\u062d\u0627\u0644\u064a\u0629 \u0641\u064a \u0639\u064a\u0627\u062f\u0627\u062a \u0627\u0644\u0634\u0628\u0643\u064a\u0629.<\/p><p>\u201c\u0648\u0623\u0636\u0627\u0641: &quot;\u0644\u0642\u062f \u0639\u0645\u0644\u0646\u0627 \u0639\u0644\u0649 \u0645\u0646\u0635\u0629 \u0625\u062f\u0627\u0631\u0629 \u0623\u0648\u0627\u0645\u0631 \u0627\u0644\u062a\u062d\u0643\u0645 \u0639\u0646 \u0628\u0639\u062f \u0644\u0623\u0643\u062b\u0631 \u0645\u0646 \u0639\u0642\u062f \u0645\u0646 \u0627\u0644\u0632\u0645\u0627\u0646&quot;.\u00a0<a href=\"https:\/\/nanostherapeutics.com\/ar\/who-we-are\/samarendra-mohanty\/\">\u0633\u0627\u0645\u0627\u0631\u064a\u0646\u062f\u0631\u0627 \u0645\u0648\u0647\u0627\u0646\u062a\u064a\u060c \u062d\u0627\u0635\u0644 \u0639\u0644\u0649 \u062f\u0631\u062c\u0629 \u0627\u0644\u062f\u0643\u062a\u0648\u0631\u0627\u0647\u060c \u0627\u0644\u0631\u0626\u064a\u0633\u060c \u0643\u0628\u064a\u0631 \u0627\u0644\u0645\u0633\u0624\u0648\u0644\u064a\u0646 \u0627\u0644\u0639\u0644\u0645\u064a\u064a\u0646\u060c \u0648\u0627\u0644\u0645\u0624\u0633\u0633 \u0627\u0644\u0645\u0634\u0627\u0631\u0643 \u0644\u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628<\/a>. &quot;\u0644\u0642\u062f \u0631\u0623\u064a\u0646\u0627 \u0647\u0630\u0627 \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u062a\u062c\u0631\u064a\u0628\u064a \u064a\u062a\u062c\u0627\u0648\u0632 \u062a\u0648\u0642\u0639\u0627\u062a\u0646\u0627 \u0641\u064a \u0627\u0644\u0645\u062e\u062a\u0628\u0631 \u0648\u0639\u0644\u0649 \u0627\u0644\u0645\u0631\u0636\u0649 \u0641\u064a \u0627\u0644\u062a\u062c\u0627\u0631\u0628 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629\u060c \u0648\u0646\u0639\u062a\u0642\u062f \u0623\u0646\u0646\u0627 \u0627\u0644\u0622\u0646 \u0623\u0642\u0631\u0628 \u062e\u0637\u0648\u0629 \u0625\u0644\u0649 \u0625\u0645\u0643\u0627\u0646\u064a\u0629 \u062a\u0642\u062f\u064a\u0645 \u0647\u0630\u0627 \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0631\u0627\u0626\u062f \u0644\u062c\u0645\u064a\u0639 \u0645\u0631\u0636\u0649 \u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a.&quot;\u201c<\/p><p>\u064a\u064f\u0639\u062f\u0651 \u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a \u0623\u062d\u062f \u0627\u0644\u0623\u0633\u0628\u0627\u0628 \u0627\u0644\u0631\u0626\u064a\u0633\u064a\u0629 \u0644\u0644\u0639\u0645\u0649 \u0628\u064a\u0646 \u0627\u0644\u0633\u0643\u0627\u0646 \u0641\u064a \u0633\u0646 \u0627\u0644\u0639\u0645\u0644 \u0641\u064a \u0627\u0644\u0648\u0644\u0627\u064a\u0627\u062a \u0627\u0644\u0645\u062a\u062d\u062f\u0629\u060c \u062d\u064a\u062b \u064a\u064f\u0635\u064a\u0628 \u0623\u0643\u062b\u0631 \u0645\u0646 100,000 \u0634\u062e\u0635\u060c \u0648\u064a\u064f\u062e\u0644\u0651\u0641 \u0623\u0643\u062b\u0631 \u0645\u0646 25,000 \u0645\u0646\u0647\u0645 \u0645\u0643\u0641\u0648\u0641\u064a\u0646 \u0642\u0627\u0646\u0648\u0646\u064a\u064b\u0627. \u064a\u0639\u062a\u0645\u062f \u0641\u0642\u062f\u0627\u0646 \u0627\u0644\u0628\u0635\u0631 \u0627\u0644\u0646\u0627\u062a\u062c \u0639\u0646 \u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a \u0628\u0634\u0643\u0644 \u0643\u0628\u064a\u0631 \u0639\u0644\u0649 \u0627\u0644\u0637\u0641\u0631\u0629 \u0627\u0644\u062c\u064a\u0646\u064a\u0629 \u0627\u0644\u0643\u0627\u0645\u0646\u0629\u060c \u0648\u0641\u064a \u0627\u0644\u0645\u062a\u0648\u0633\u0637\u060c \u064a\u0641\u0642\u062f \u0645\u0631\u0636\u0649 \u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a \u0633\u0637\u0631\u064b\u0627 \u0648\u0627\u062d\u062f\u064b\u0627 \u0645\u0646 \u0627\u0644\u0631\u0624\u064a\u0629 \u0639\u0644\u0649 \u0644\u0648\u062d\u0629 \u0641\u062d\u0635 \u0627\u0644\u0646\u0638\u0631 \u0643\u0644 \u062b\u0644\u0627\u062b \u0633\u0646\u0648\u0627\u062a \u062a\u0642\u0631\u064a\u0628\u064b\u0627\u060c \u0648\u062a\u064f\u0635\u0628\u062d \u063a\u0627\u0644\u0628\u064a\u0629 \u0627\u0644\u0645\u0631\u0636\u0649 \u0645\u0643\u0641\u0648\u0641\u064a\u0646 \u0642\u0627\u0646\u0648\u0646\u064a\u064b\u0627 (\u0623\u0642\u0644 \u0645\u0646 20\/200) \u0628\u062d\u0644\u0648\u0644 \u0633\u0646 \u0627\u0644\u0633\u062a\u064a\u0646.<\/p><p>\u201c&quot;\u0643\u0627\u0646 \u0623\u062d\u062f \u0623\u0635\u0639\u0628 \u062c\u0648\u0627\u0646\u0628 \u0645\u0633\u064a\u0631\u062a\u064a \u0627\u0644\u0645\u0647\u0646\u064a\u0629 \u0628\u0623\u0643\u0645\u0644\u0647\u0627 \u0647\u0648 \u0625\u062e\u0628\u0627\u0631 \u0627\u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u0645\u0635\u0627\u0628\u064a\u0646 \u0628\u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a \u0628\u0623\u0646\u0647 \u0644\u0627 \u064a\u0648\u062c\u062f \u0639\u0644\u0627\u062c \u062a\u0631\u0645\u064a\u0645\u064a \u0645\u062a\u0627\u062d \u0644\u0623\u0646\u0647\u0645 \u064a\u0639\u0627\u0646\u0648\u0646 \u0645\u0646 \u0641\u0642\u062f\u0627\u0646 \u062a\u062f\u0631\u064a\u062c\u064a \u0648\u063a\u064a\u0631 \u0642\u0627\u0628\u0644 \u0644\u0644\u0639\u0643\u0633 \u0648\u062f\u0627\u0626\u0645 \u0644\u0644\u0628\u0635\u0631&quot;\u060c <a href=\"https:\/\/nanostherapeutics.com\/ar\/who-we-are\/allen-ho-vac\/\">\u0627\u0644\u062f\u0643\u062a\u0648\u0631 \u0623\u0644\u064a\u0646 \u0633\u064a. \u0647\u0648\u060c \u0637\u0628\u064a\u0628\u060c \u0645\u062f\u064a\u0631 \u0623\u0628\u062d\u0627\u062b \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0641\u064a \u0645\u0633\u062a\u0634\u0641\u0649 \u0648\u064a\u0644\u0632 \u0644\u0644\u0639\u064a\u0648\u0646 \u0648\u0643\u0628\u064a\u0631 \u0627\u0644\u0645\u0633\u062a\u0634\u0627\u0631\u064a\u0646 \u0627\u0644\u0637\u0628\u064a\u064a\u0646 \u0644\u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628<\/a>. &quot;\u0627\u0633\u062a\u0646\u0627\u062f\u064b\u0627 \u0625\u0644\u0649 \u0627\u0644\u0639\u0644\u0648\u0645 \u0645\u0627 \u0642\u0628\u0644 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 \u0648\u0627\u0644\u0623\u062f\u0644\u0629 \u0641\u064a \u0627\u0644\u062a\u062c\u0627\u0631\u0628 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629\u060c \u064a\u0645\u062b\u0644 MCO-010 \u062a\u062d\u0648\u0644\u064b\u0627 \u0646\u0645\u0648\u0630\u062c\u064a\u064b\u0627 \u0647\u0627\u0645\u064b\u0627 \u0645\u062d\u062a\u0645\u0644\u0627\u064b \u0644\u0644\u0645\u0631\u0636\u0649 \u0648\u0623\u062e\u0635\u0627\u0626\u064a\u064a \u0627\u0644\u0634\u0628\u0643\u064a\u0629\u060c \u0645\u0645\u0627 \u064a\u0648\u0641\u0631 \u0627\u0644\u0623\u0645\u0644 \u0641\u064a \u062a\u062d\u0633\u064a\u0646 \u0630\u064a \u0645\u063a\u0632\u0649 \u0641\u064a \u0646\u0648\u0639\u064a\u0629 \u062d\u064a\u0627\u0629 \u0645\u0631\u0636\u0649 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0623\u0643\u062b\u0631 \u0627\u062d\u062a\u064a\u0627\u062c\u064b\u0627 \u0639\u0644\u0649 \u0627\u0644\u0625\u0637\u0644\u0627\u0642.&quot;\u201c<\/p><p>\u0641\u064a \u062a\u062c\u0631\u0628\u0629 RESTORE \u0627\u0644\u0645\u062d\u0648\u0631\u064a\u0629 \u0645\u0646 \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0646\u064a\u0629 (\u0628) \u0627\u0644\u062a\u064a \u0623\u062c\u0631\u062a\u0647\u0627 \u0634\u0631\u0643\u0629 Nanoscope\u060c \u062d\u0642\u0642 \u062f\u0648\u0627\u0621 MCO-010 \u0623\u0647\u062f\u0627\u0641\u0647 \u0627\u0644\u0631\u0626\u064a\u0633\u064a\u0629 \u0627\u0644\u0645\u062a\u0639\u0644\u0642\u0629 \u0628\u0623\u0641\u0636\u0644 \u062d\u062f\u0629 \u0628\u0635\u0631\u064a\u0629 \u0645\u0635\u062d\u062d\u0629 \u0641\u064a \u0643\u0644\u062a\u0627 \u0645\u062c\u0645\u0648\u0639\u062a\u064a \u0627\u0644\u062c\u0631\u0639\u0627\u062a \u0628\u0639\u062f 52 \u0623\u0633\u0628\u0648\u0639\u064b\u0627 \u0645\u0642\u0627\u0631\u0646\u0629\u064b \u0628\u0645\u062c\u0645\u0648\u0639\u0629 \u0627\u0644\u062a\u062d\u0643\u0645 \u0627\u0644\u0648\u0647\u0645\u064a\u0629\u060c \u062d\u064a\u062b \u062d\u0642\u0642 \u062a\u062d\u0633\u0646\u064b\u0627 \u0641\u064a \u062d\u062f\u0629 \u0627\u0644\u0628\u0635\u0631 \u0639\u0646 \u062e\u0637 \u0627\u0644\u0623\u0633\u0627\u0633 \u064a\u0632\u064a\u062f \u0639\u0646 0.3 LogMAR\u060c \u0648\u0647\u064a \u0646\u062a\u064a\u062c\u0629 \u062a\u0639\u0627\u062f\u0644 \u062b\u0644\u0627\u062b\u0629 \u0623\u0633\u0637\u0631 \u0623\u0648 \u0623\u0643\u062b\u0631 \u0639\u0644\u0649 \u0644\u0648\u062d\u0629 \u0641\u062d\u0635 \u0627\u0644\u0646\u0638\u0631. \u0648\u0641\u064a \u0627\u0644\u0645\u062a\u0627\u0628\u0639\u0629 \u0637\u0648\u064a\u0644\u0629 \u0627\u0644\u0623\u0645\u062f \u0627\u0644\u062c\u0627\u0631\u064a\u0629\u060c \u0644\u0648\u062d\u0638 \u062a\u062d\u0633\u0646 \u0641\u064a \u062d\u062f\u0629 \u0627\u0644\u0628\u0635\u0631 \u0639\u0644\u0649 \u0645\u062f\u0649 3 \u0633\u0646\u0648\u0627\u062a\u060c \u062f\u0648\u0646 \u0627\u0644\u0625\u0628\u0644\u0627\u063a \u0639\u0646 \u0623\u064a \u0622\u062b\u0627\u0631 \u062c\u0627\u0646\u0628\u064a\u0629 \u062e\u0637\u064a\u0631\u0629 \u0641\u064a \u0627\u0644\u0639\u064a\u0648\u0646 \u0627\u0644\u0645\u0639\u0627\u0644\u062c\u0629. \u0648\u0645\u0646 \u0627\u0644\u0645\u0642\u0631\u0631 \u0625\u062c\u0631\u0627\u0621 \u0645\u062a\u0627\u0628\u0639\u0629 \u0645\u062a\u0639\u062f\u062f\u0629 \u0627\u0644\u0633\u0646\u0648\u0627\u062a \u0644\u0647\u0624\u0644\u0627\u0621 \u0627\u0644\u0645\u0631\u0636\u0649 \u0644\u062a\u0642\u064a\u064a\u0645 \u0641\u0639\u0627\u0644\u064a\u0629 \u0627\u0644\u062f\u0648\u0627\u0621 \u0648\u0633\u0644\u0627\u0645\u062a\u0647 \u0639\u0644\u0649 \u0627\u0644\u0645\u062f\u0649 \u0627\u0644\u0637\u0648\u064a\u0644.<\/p><p>\u201c\u0648\u062e\u0644\u0635 \u0627\u0644\u062a\u0642\u0631\u064a\u0631 \u0625\u0644\u0649 \u0627\u0644\u0642\u0648\u0644: &quot;\u0625\u0646\u0647\u0627 \u0627\u0644\u0645\u0631\u0629 \u0627\u0644\u0623\u0648\u0644\u0649 \u0627\u0644\u062a\u064a \u0633\u062a\u0642\u0648\u0645 \u0641\u064a\u0647\u0627 \u0625\u062f\u0627\u0631\u0629 \u0627\u0644\u063a\u0630\u0627\u0621 \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0628\u062a\u0642\u064a\u064a\u0645 \u0637\u0644\u0628 \u0644\u0644\u062d\u0635\u0648\u0644 \u0639\u0644\u0649 \u0639\u0644\u0627\u062c \u063a\u064a\u0631 \u0645\u0631\u062a\u0628\u0637 \u0628\u062c\u064a\u0646 \u0645\u0639\u064a\u0646 \u0644\u0623\u0645\u0631\u0627\u0636 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0648\u0631\u0627\u062b\u064a\u0629&quot;. <a href=\"https:\/\/nanostherapeutics.com\/ar\/who-we-are\/glenn-sblendorio-bod\/\">\u063a\u0644\u064a\u0646 \u0633\u0628\u0644\u064a\u0646\u062f\u0648\u0631\u064a\u0648\u060c \u0631\u0626\u064a\u0633 \u0645\u062c\u0644\u0633 \u0625\u062f\u0627\u0631\u0629 \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628<\/a>. &quot;\u0646\u062d\u0646 \u0648\u0627\u062b\u0642\u0648\u0646 \u0645\u0646 \u0628\u064a\u0627\u0646\u0627\u062a\u0646\u0627 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629\u060c \u0648\u0627\u0644\u062a\u064a \u0646\u0639\u062a\u0642\u062f \u0623\u0646\u0647\u0627 \u0633\u062a\u0634\u0643\u0644 \u0641\u062c\u0631 \u0639\u0647\u062f \u062c\u062f\u064a\u062f \u0641\u064a \u0631\u0639\u0627\u064a\u0629 \u0627\u0644\u0634\u0628\u0643\u064a\u0629. \u0647\u062f\u0641\u0646\u0627 \u0647\u0648 \u0625\u0639\u0627\u062f\u0629 \u0627\u0644\u0623\u0645\u0644 \u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a\u060c \u0648\u0641\u064a \u0646\u0647\u0627\u064a\u0629 \u0627\u0644\u0645\u0637\u0627\u0641 \u0644\u0644\u0639\u062f\u064a\u062f \u0645\u0646 \u062d\u0627\u0644\u0627\u062a \u062a\u0646\u0643\u0633 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0623\u062e\u0631\u0649.&quot;\u201c \u00a0<\/p><p>\u0644\u0644\u0645\u0632\u064a\u062f \u0645\u0646 \u0627\u0644\u0645\u0639\u0644\u0648\u0645\u0627\u062a \u062d\u0648\u0644 MCO-010 \u0648\u0634\u0631\u0643\u0629 Nanoscope Therapeutics\u060c \u062a\u0641\u0636\u0644 \u0628\u0632\u064a\u0627\u0631\u0629: <a href=\"https:\/\/url.avanan.click\/v2\/___https:\/www.nanostherapeutics.com___.YXAzOm5hbm9zY29wZXRoZXJhcGV1dGljczphOm86ODBiMzBmNTQ3ZmEyNzYzOWY5NDk5ODg3OWY5NDBlOTQ6Njo0YmI4OjlmOTc0YTdjYzdjMmFlZTQ3YTY5MDhkMmYxZTllZThiYWY4MzU4ZDI1YzMyMWViMTIyMWQ2YzViNWNjMjZhNTA6cDpUOk4\">www.nanostherapeutics.com<\/a>.<\/p><p><strong>\u0646\u0628\u0630\u0629 \u0639\u0646 \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633<\/strong><\/p><p>\u062a\u0639\u0645\u0644 \u0634\u0631\u0643\u0629 Nanoscope Therapeutics \u0639\u0644\u0649 \u062a\u0637\u0648\u064a\u0631 \u0639\u0644\u0627\u062c \u0628\u0635\u0631\u064a \u0648\u0631\u0627\u062b\u064a \u0644\u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631\u060c \u0644\u0627 \u064a\u0639\u062a\u0645\u062f \u0639\u0644\u0649 \u0627\u0644\u062c\u064a\u0646\u0627\u062a\u060c \u0644\u0645\u0644\u0627\u064a\u064a\u0646 \u0627\u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u0630\u064a\u0646 \u0641\u0642\u062f\u0648\u0627 \u0628\u0635\u0631\u0647\u0645 \u0628\u0633\u0628\u0628 \u0623\u0645\u0631\u0627\u0636 \u062a\u0646\u0643\u0633 \u0627\u0644\u0634\u0628\u0643\u064a\u0629. \u0648\u0630\u0644\u0643 \u0628\u0639\u062f \u0627\u0644\u0646\u062a\u0627\u0626\u062c \u0627\u0644\u0625\u064a\u062c\u0627\u0628\u064a\u0629 \u0627\u0644\u062a\u064a \u062d\u0642\u0642\u062a\u0647\u0627 \u062a\u062c\u0631\u0628\u0629 RESTORE \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 \u0645\u062a\u0639\u062f\u062f\u0629 \u0627\u0644\u0645\u0631\u0627\u0643\u0632\u060c \u0627\u0644\u0639\u0634\u0648\u0627\u0626\u064a\u0629\u060c \u0645\u0632\u062f\u0648\u062c\u0629 \u0627\u0644\u062a\u0639\u0645\u064a\u0629\u060c \u0648\u0627\u0644\u0645\u0636\u0628\u0648\u0637\u0629 \u0628\u0627\u0644\u063a\u0641\u0644\u060c \u0645\u0646 \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0646\u064a\u0629 (\u0628) \u0644\u0639\u0644\u0627\u062c \u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a (RP).<a href=\"https:\/\/url.avanan.click\/v2\/___https:\/clinicaltrials.gov\/study\/NCT04945772___.YXAzOm5hbm9zY29wZXRoZXJhcGV1dGljczphOm86ODBiMzBmNTQ3ZmEyNzYzOWY5NDk5ODg3OWY5NDBlOTQ6Njo0YWVjOmU5YTIyOGNiZDRhMzQ3NzJkNWE0NDg0MjliN2JlZjMxN2Q1ZmM4NWU2MTBiOWQwNjZkM2ZjZDZkMGQ5NjVjMWI6cDpUOk4\">NCT04945772<\/a>\u0628\u062f\u0623\u062a \u0627\u0644\u0634\u0631\u0643\u0629 \u0625\u062c\u0631\u0627\u0621\u0627\u062a \u062a\u0642\u062f\u064a\u0645 \u0637\u0644\u0628 \u062a\u0631\u062e\u064a\u0635 \u0628\u064a\u0648\u0644\u0648\u062c\u064a (BLA) \u0625\u0644\u0649 \u0625\u062f\u0627\u0631\u0629 \u0627\u0644\u063a\u0630\u0627\u0621 \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a\u0629 (FDA). \u0641\u064a \u062d\u0627\u0644 \u0627\u0644\u0645\u0648\u0627\u0641\u0642\u0629\u060c \u064a\u064f\u062d\u062a\u0645\u0644 \u0623\u0646 \u064a\u0635\u0628\u062d MCO-010 \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u0642\u064a\u0627\u0633\u064a \u0644\u0645\u0631\u0636\u0649 \u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a (RP)\u060c \u062d\u064a\u062b \u064a\u064f\u0639\u0637\u0649 \u0643\u062d\u0642\u0646\u0629 \u0648\u0627\u062d\u062f\u0629 \u0641\u064a \u0627\u0644\u0639\u064a\u0627\u062f\u0629 \u062f\u0648\u0646 \u0627\u0644\u062d\u0627\u062c\u0629 \u0625\u0644\u0649 \u0627\u062e\u062a\u0628\u0627\u0631\u0627\u062a \u062c\u064a\u0646\u064a\u0629. \u0643\u0645\u0627 \u0623\u0638\u0647\u0631\u062a \u0627\u0644\u0634\u0631\u0643\u0629 \u0646\u062a\u0627\u0626\u062c \u0648\u0627\u0639\u062f\u0629 \u0641\u064a \u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0646\u064a\u0629 \u0645\u0646 \u0627\u0644\u062a\u062c\u0631\u0628\u0629 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 STARLIGHT \u0644\u0640 MCO-010 \u0641\u064a \u0639\u0644\u0627\u062c \u0645\u0631\u0636 \u0633\u062a\u0627\u0631\u063a\u0627\u0631\u062f\u062a (SD).<a href=\"https:\/\/url.avanan.click\/v2\/___https:\/clinicaltrials.gov\/study\/NCT05417126___.YXAzOm5hbm9zY29wZXRoZXJhcGV1dGljczphOm86ODBiMzBmNTQ3ZmEyNzYzOWY5NDk5ODg3OWY5NDBlOTQ6NjpjMWRkOmVmOTBkMjllMDdkZTAwZGRhNmY0NGIxZWVmYzExOWI2OWU5ZGY3YTRjYTQ5ZTMyZjZlOTQxYTJjOGZkMjM4YmM6cDpUOk4\">NCT05417126<\/a>) \u0648\u062a\u062e\u0637\u0637 \u0644\u0628\u062f\u0621 <a href=\"https:\/\/url.avanan.click\/v2\/___https:\/nanostherapeutics.com\/2024\/09\/12\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration\/___.YXAzOm5hbm9zY29wZXRoZXJhcGV1dGljczphOm86ODBiMzBmNTQ3ZmEyNzYzOWY5NDk5ODg3OWY5NDBlOTQ6NjoxM2E1OjdmZGE1NmRiYjg5MmIyYzAzOGRlYzc4YWY3ZmRlZmNmMjhlZjNkZmQ2Y2Y0MTE1ZWQ2MzMwMDg1MTAwMDAwYzk6cDpUOk4\">\u0627\u0644\u0645\u0631\u062d\u0644\u0629 \u0627\u0644\u062b\u0627\u0644\u062b\u0629 \u0645\u0646 \u0627\u0644\u062a\u062c\u0631\u0628\u0629 \u0627\u0644\u062a\u0633\u062c\u064a\u0644\u064a\u0629<\/a> \u0641\u064a \u0639\u0627\u0645 2025. \u062d\u0635\u0644 MCO-010 \u0639\u0644\u0649 \u062a\u0635\u0646\u064a\u0641\u0627\u062a \u0627\u0644\u0645\u0633\u0627\u0631 \u0627\u0644\u0633\u0631\u064a\u0639 \u0648\u062f\u0648\u0627\u0621 \u0627\u0644\u064a\u062a\u064a\u0645 \u0645\u0646 \u0625\u062f\u0627\u0631\u0629 \u0627\u0644\u063a\u0630\u0627\u0621 \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a\u0629 \u0644\u0643\u0644 \u0645\u0646 RP \u0648SD. \u062a\u0634\u0645\u0644 \u0627\u0644\u0628\u0631\u0627\u0645\u062c \u0645\u0627 \u0642\u0628\u0644 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629 \u0627\u0644\u0639\u0645\u0649 \u0627\u0644\u062e\u0644\u0642\u064a \u0644\u0644\u064a\u0628\u0631 (LCA)\u060c \u0641\u064a \u062f\u0631\u0627\u0633\u0627\u062a \u062a\u0645\u0643\u064a\u0646 IND\u060c \u0628\u0627\u0644\u0625\u0636\u0627\u0641\u0629 \u0625\u0644\u0649 \u0623\u0635\u0644 \u062c\u0627\u0647\u0632 \u0644\u0640 IND \u0644\u0644\u0636\u0645\u0648\u0631 \u0627\u0644\u062c\u063a\u0631\u0627\u0641\u064a (GA).\u00a0<\/p><p><strong>\u0627\u062a\u0635\u0627\u0644:<\/strong><\/p><p>\u0639\u0644\u0627\u062c\u0627\u062a \u0627\u0644\u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628<br \/>(817) 857-1186<br \/>PR@nanostherapeutics.com<\/p><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>First modules of BLA submitted to FDA under rolling review, with full submission anticipated in early 2026 MCO-010 BLA for retinitis pigmentosa is eligible for priority review based on fast-track designation If approved, MCO-010 has the potential to be the standard of care for retinitis pigmentosa, delivered via a one-time, in-office intravitreal injection with the [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":9185,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-9121","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for MCO-010, the First Gene-Agnostic Therapy to Treat Retinitis Pigmentosa - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/ar\/2025\/07\/14\/nanoscope-therapeutics-initiates-rolling-submission-of-biologics-license-application-to-fda-for-mco-010-the-first-gene-agnostic-therapy-to-treat-retinitis-pigmentosa\/\" \/>\n<meta property=\"og:locale\" content=\"ar_AR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for MCO-010, the First Gene-Agnostic Therapy to Treat Retinitis Pigmentosa - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/ar\/2025\/07\/14\/nanoscope-therapeutics-initiates-rolling-submission-of-biologics-license-application-to-fda-for-mco-010-the-first-gene-agnostic-therapy-to-treat-retinitis-pigmentosa\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-14T11:06:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-23T23:39:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"\u0643\u064f\u062a\u0628 \u0628\u0648\u0627\u0633\u0637\u0629\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u0648\u0642\u062a \u0627\u0644\u0642\u0631\u0627\u0621\u0629 \u0627\u0644\u0645\u064f\u0642\u062f\u0651\u0631\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 \u062f\u0642\u0627\u0626\u0642\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/14\\\/nanoscope-therapeutics-initiates-rolling-submission-of-biologics-license-application-to-fda-for-mco-010-the-first-gene-agnostic-therapy-to-treat-retinitis-pigmentosa\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/14\\\/nanoscope-therapeutics-initiates-rolling-submission-of-biologics-license-application-to-fda-for-mco-010-the-first-gene-agnostic-therapy-to-treat-retinitis-pigmentosa\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for MCO-010, the First Gene-Agnostic Therapy to Treat Retinitis Pigmentosa\",\"datePublished\":\"2025-07-14T11:06:03+00:00\",\"dateModified\":\"2025-07-23T23:39:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/14\\\/nanoscope-therapeutics-initiates-rolling-submission-of-biologics-license-application-to-fda-for-mco-010-the-first-gene-agnostic-therapy-to-treat-retinitis-pigmentosa\\\/\"},\"wordCount\":958,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/14\\\/nanoscope-therapeutics-initiates-rolling-submission-of-biologics-license-application-to-fda-for-mco-010-the-first-gene-agnostic-therapy-to-treat-retinitis-pigmentosa\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_25-LI_BLA_V1REV2.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"ar\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/14\\\/nanoscope-therapeutics-initiates-rolling-submission-of-biologics-license-application-to-fda-for-mco-010-the-first-gene-agnostic-therapy-to-treat-retinitis-pigmentosa\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/14\\\/nanoscope-therapeutics-initiates-rolling-submission-of-biologics-license-application-to-fda-for-mco-010-the-first-gene-agnostic-therapy-to-treat-retinitis-pigmentosa\\\/\",\"name\":\"Nanoscope Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for MCO-010, the First Gene-Agnostic Therapy to Treat Retinitis Pigmentosa - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/14\\\/nanoscope-therapeutics-initiates-rolling-submission-of-biologics-license-application-to-fda-for-mco-010-the-first-gene-agnostic-therapy-to-treat-retinitis-pigmentosa\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/14\\\/nanoscope-therapeutics-initiates-rolling-submission-of-biologics-license-application-to-fda-for-mco-010-the-first-gene-agnostic-therapy-to-treat-retinitis-pigmentosa\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_25-LI_BLA_V1REV2.jpg\",\"datePublished\":\"2025-07-14T11:06:03+00:00\",\"dateModified\":\"2025-07-23T23:39:41+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/14\\\/nanoscope-therapeutics-initiates-rolling-submission-of-biologics-license-application-to-fda-for-mco-010-the-first-gene-agnostic-therapy-to-treat-retinitis-pigmentosa\\\/#breadcrumb\"},\"inLanguage\":\"ar\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/14\\\/nanoscope-therapeutics-initiates-rolling-submission-of-biologics-license-application-to-fda-for-mco-010-the-first-gene-agnostic-therapy-to-treat-retinitis-pigmentosa\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ar\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/14\\\/nanoscope-therapeutics-initiates-rolling-submission-of-biologics-license-application-to-fda-for-mco-010-the-first-gene-agnostic-therapy-to-treat-retinitis-pigmentosa\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_25-LI_BLA_V1REV2.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_25-LI_BLA_V1REV2.jpg\",\"width\":1200,\"height\":1200},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/07\\\/14\\\/nanoscope-therapeutics-initiates-rolling-submission-of-biologics-license-application-to-fda-for-mco-010-the-first-gene-agnostic-therapy-to-treat-retinitis-pigmentosa\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for MCO-010, the First Gene-Agnostic Therapy to Treat Retinitis Pigmentosa\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ar\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ar\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u0628\u062f\u0623\u062a \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633 \u0628\u062a\u0642\u062f\u064a\u0645 \u0637\u0644\u0628 \u062a\u0631\u062e\u064a\u0635 \u0628\u064a\u0648\u0644\u0648\u062c\u064a \u062a\u062f\u0631\u064a\u062c\u064a \u0625\u0644\u0649 \u0625\u062f\u0627\u0631\u0629 \u0627\u0644\u063a\u0630\u0627\u0621 \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a\u0629 (FDA) \u0644\u0639\u0644\u0627\u062c MCO-010\u060c \u0648\u0647\u0648 \u0623\u0648\u0644 \u0639\u0644\u0627\u062c \u063a\u064a\u0631 \u0645\u0631\u062a\u0628\u0637 \u0628\u062c\u064a\u0646 \u0645\u0639\u064a\u0646 \u0644\u0639\u0644\u0627\u062c \u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a - \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633","description":"\u062a\u064f\u0639\u062f\u0651 \u0645\u0646\u0635\u0629 \u0627\u0644\u0623\u0648\u0628\u0633\u064a\u0646 \u0645\u062a\u0639\u062f\u062f\u0629 \u0627\u0644\u062e\u0635\u0627\u0626\u0635 (MCO) \u0627\u0644\u062e\u0627\u0635\u0629 \u0628\u0646\u0627 \u0627\u0644\u0623\u0648\u0644\u0649 \u0645\u0646 \u0646\u0648\u0639\u0647\u0627 \u0627\u0644\u062a\u064a \u0623\u062b\u0628\u062a\u062a \u0642\u062f\u0631\u062a\u0647\u0627 \u0639\u0644\u0649 \u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631 \u0644\u0645\u0631\u0636\u0649 \u0623\u0645\u0631\u0627\u0636 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0630\u064a\u0646 \u064a\u0639\u0627\u0646\u0648\u0646 \u0645\u0646 \u0641\u0642\u062f\u0627\u0646 \u0634\u062f\u064a\u062f \u0644\u0644\u0628\u0635\u0631 \u0641\u064a \u0627\u0644\u062a\u062c\u0627\u0631\u0628 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629. \u0648\u0642\u062f \u0637\u0648\u0651\u0631\u062a \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062a\u0642\u0646\u064a\u0629 MCO-010\u060c \u0648\u0647\u064a \u0627\u0644\u062a\u0642\u0646\u064a\u0629 \u0627\u0644\u0623\u0648\u0644\u0649 \u0648\u0627\u0644\u0648\u062d\u064a\u062f\u0629 \u0645\u0646 \u0646\u0648\u0639\u0647\u0627 \u0641\u064a \u0645\u062c\u0627\u0644 \u0639\u0644\u0645 \u0627\u0644\u0628\u0635\u0631\u064a\u0627\u062a \u0627\u0644\u0648\u0631\u0627\u062b\u064a\u0629\u060c \u0648\u0627\u0644\u062a\u064a \u062a\u062a\u0645\u064a\u0632 \u0628\u0646\u0637\u0627\u0642\u0647\u0627 \u0627\u0644\u0648\u0627\u0633\u0639 \u0648\u0627\u0633\u062a\u062c\u0627\u0628\u062a\u0647\u0627 \u0627\u0644\u0633\u0631\u064a\u0639\u0629 \u0648\u062d\u0633\u0627\u0633\u064a\u062a\u0647\u0627 \u0627\u0644\u0641\u0627\u0626\u0642\u0629\u060c \u0648\u0647\u064a \u062a\u0642\u0646\u064a\u0629 \u0645\u0633\u062a\u0642\u0644\u0629 \u0639\u0646 \u0627\u0644\u062c\u064a\u0646\u0627\u062a \u0627\u0644\u0645\u0633\u062a\u062e\u062f\u0645\u0629 \u0641\u064a \u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/ar\/2025\/07\/14\/nanoscope-therapeutics-initiates-rolling-submission-of-biologics-license-application-to-fda-for-mco-010-the-first-gene-agnostic-therapy-to-treat-retinitis-pigmentosa\/","og_locale":"ar_AR","og_type":"article","og_title":"Nanoscope Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for MCO-010, the First Gene-Agnostic Therapy to Treat Retinitis Pigmentosa - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/ar\/2025\/07\/14\/nanoscope-therapeutics-initiates-rolling-submission-of-biologics-license-application-to-fda-for-mco-010-the-first-gene-agnostic-therapy-to-treat-retinitis-pigmentosa\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2025-07-14T11:06:03+00:00","article_modified_time":"2025-07-23T23:39:41+00:00","og_image":[{"width":1200,"height":242,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"\u0643\u064f\u062a\u0628 \u0628\u0648\u0627\u0633\u0637\u0629":"Nanoscope Therapeutics","\u0648\u0642\u062a \u0627\u0644\u0642\u0631\u0627\u0621\u0629 \u0627\u0644\u0645\u064f\u0642\u062f\u0651\u0631":"5 \u062f\u0642\u0627\u0626\u0642"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2025\/07\/14\/nanoscope-therapeutics-initiates-rolling-submission-of-biologics-license-application-to-fda-for-mco-010-the-first-gene-agnostic-therapy-to-treat-retinitis-pigmentosa\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2025\/07\/14\/nanoscope-therapeutics-initiates-rolling-submission-of-biologics-license-application-to-fda-for-mco-010-the-first-gene-agnostic-therapy-to-treat-retinitis-pigmentosa\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for MCO-010, the First Gene-Agnostic Therapy to Treat Retinitis Pigmentosa","datePublished":"2025-07-14T11:06:03+00:00","dateModified":"2025-07-23T23:39:41+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/07\/14\/nanoscope-therapeutics-initiates-rolling-submission-of-biologics-license-application-to-fda-for-mco-010-the-first-gene-agnostic-therapy-to-treat-retinitis-pigmentosa\/"},"wordCount":958,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/07\/14\/nanoscope-therapeutics-initiates-rolling-submission-of-biologics-license-application-to-fda-for-mco-010-the-first-gene-agnostic-therapy-to-treat-retinitis-pigmentosa\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_25-LI_BLA_V1REV2.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"ar"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2025\/07\/14\/nanoscope-therapeutics-initiates-rolling-submission-of-biologics-license-application-to-fda-for-mco-010-the-first-gene-agnostic-therapy-to-treat-retinitis-pigmentosa\/","url":"https:\/\/nanostherapeutics.com\/2025\/07\/14\/nanoscope-therapeutics-initiates-rolling-submission-of-biologics-license-application-to-fda-for-mco-010-the-first-gene-agnostic-therapy-to-treat-retinitis-pigmentosa\/","name":"\u0628\u062f\u0623\u062a \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633 \u0628\u062a\u0642\u062f\u064a\u0645 \u0637\u0644\u0628 \u062a\u0631\u062e\u064a\u0635 \u0628\u064a\u0648\u0644\u0648\u062c\u064a \u062a\u062f\u0631\u064a\u062c\u064a \u0625\u0644\u0649 \u0625\u062f\u0627\u0631\u0629 \u0627\u0644\u063a\u0630\u0627\u0621 \u0648\u0627\u0644\u062f\u0648\u0627\u0621 \u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a\u0629 (FDA) \u0644\u0639\u0644\u0627\u062c MCO-010\u060c \u0648\u0647\u0648 \u0623\u0648\u0644 \u0639\u0644\u0627\u062c \u063a\u064a\u0631 \u0645\u0631\u062a\u0628\u0637 \u0628\u062c\u064a\u0646 \u0645\u0639\u064a\u0646 \u0644\u0639\u0644\u0627\u062c \u0627\u0644\u062a\u0647\u0627\u0628 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0635\u0628\u0627\u063a\u064a - \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/07\/14\/nanoscope-therapeutics-initiates-rolling-submission-of-biologics-license-application-to-fda-for-mco-010-the-first-gene-agnostic-therapy-to-treat-retinitis-pigmentosa\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/07\/14\/nanoscope-therapeutics-initiates-rolling-submission-of-biologics-license-application-to-fda-for-mco-010-the-first-gene-agnostic-therapy-to-treat-retinitis-pigmentosa\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_25-LI_BLA_V1REV2.jpg","datePublished":"2025-07-14T11:06:03+00:00","dateModified":"2025-07-23T23:39:41+00:00","description":"\u062a\u064f\u0639\u062f\u0651 \u0645\u0646\u0635\u0629 \u0627\u0644\u0623\u0648\u0628\u0633\u064a\u0646 \u0645\u062a\u0639\u062f\u062f\u0629 \u0627\u0644\u062e\u0635\u0627\u0626\u0635 (MCO) \u0627\u0644\u062e\u0627\u0635\u0629 \u0628\u0646\u0627 \u0627\u0644\u0623\u0648\u0644\u0649 \u0645\u0646 \u0646\u0648\u0639\u0647\u0627 \u0627\u0644\u062a\u064a \u0623\u062b\u0628\u062a\u062a \u0642\u062f\u0631\u062a\u0647\u0627 \u0639\u0644\u0649 \u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631 \u0644\u0645\u0631\u0636\u0649 \u0623\u0645\u0631\u0627\u0636 \u0627\u0644\u0634\u0628\u0643\u064a\u0629 \u0627\u0644\u0630\u064a\u0646 \u064a\u0639\u0627\u0646\u0648\u0646 \u0645\u0646 \u0641\u0642\u062f\u0627\u0646 \u0634\u062f\u064a\u062f \u0644\u0644\u0628\u0635\u0631 \u0641\u064a \u0627\u0644\u062a\u062c\u0627\u0631\u0628 \u0627\u0644\u0633\u0631\u064a\u0631\u064a\u0629. \u0648\u0642\u062f \u0637\u0648\u0651\u0631\u062a \u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062a\u0642\u0646\u064a\u0629 MCO-010\u060c \u0648\u0647\u064a \u0627\u0644\u062a\u0642\u0646\u064a\u0629 \u0627\u0644\u0623\u0648\u0644\u0649 \u0648\u0627\u0644\u0648\u062d\u064a\u062f\u0629 \u0645\u0646 \u0646\u0648\u0639\u0647\u0627 \u0641\u064a \u0645\u062c\u0627\u0644 \u0639\u0644\u0645 \u0627\u0644\u0628\u0635\u0631\u064a\u0627\u062a \u0627\u0644\u0648\u0631\u0627\u062b\u064a\u0629\u060c \u0648\u0627\u0644\u062a\u064a \u062a\u062a\u0645\u064a\u0632 \u0628\u0646\u0637\u0627\u0642\u0647\u0627 \u0627\u0644\u0648\u0627\u0633\u0639 \u0648\u0627\u0633\u062a\u062c\u0627\u0628\u062a\u0647\u0627 \u0627\u0644\u0633\u0631\u064a\u0639\u0629 \u0648\u062d\u0633\u0627\u0633\u064a\u062a\u0647\u0627 \u0627\u0644\u0641\u0627\u0626\u0642\u0629\u060c \u0648\u0647\u064a \u062a\u0642\u0646\u064a\u0629 \u0645\u0633\u062a\u0642\u0644\u0629 \u0639\u0646 \u0627\u0644\u062c\u064a\u0646\u0627\u062a \u0627\u0644\u0645\u0633\u062a\u062e\u062f\u0645\u0629 \u0641\u064a \u0627\u0633\u062a\u0639\u0627\u062f\u0629 \u0627\u0644\u0628\u0635\u0631.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2025\/07\/14\/nanoscope-therapeutics-initiates-rolling-submission-of-biologics-license-application-to-fda-for-mco-010-the-first-gene-agnostic-therapy-to-treat-retinitis-pigmentosa\/#breadcrumb"},"inLanguage":"ar","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2025\/07\/14\/nanoscope-therapeutics-initiates-rolling-submission-of-biologics-license-application-to-fda-for-mco-010-the-first-gene-agnostic-therapy-to-treat-retinitis-pigmentosa\/"]}]},{"@type":"ImageObject","inLanguage":"ar","@id":"https:\/\/nanostherapeutics.com\/2025\/07\/14\/nanoscope-therapeutics-initiates-rolling-submission-of-biologics-license-application-to-fda-for-mco-010-the-first-gene-agnostic-therapy-to-treat-retinitis-pigmentosa\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_25-LI_BLA_V1REV2.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_25-LI_BLA_V1REV2.jpg","width":1200,"height":1200},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2025\/07\/14\/nanoscope-therapeutics-initiates-rolling-submission-of-biologics-license-application-to-fda-for-mco-010-the-first-gene-agnostic-therapy-to-treat-retinitis-pigmentosa\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for MCO-010, the First Gene-Agnostic Therapy to Treat Retinitis Pigmentosa"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"\u0639\u0644\u0627\u062c\u0627\u062a \u0627\u0644\u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628","description":"\u0625\u0639\u0627\u062f\u0629 \u0646\u0648\u0631 \u0627\u0644\u0623\u0645\u0644","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ar"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"\u0634\u0631\u0643\u0629 \u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628 \u062b\u064a\u0631\u0627\u0628\u064a\u0648\u062a\u0643\u0633","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"ar","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"\u0639\u0644\u0627\u062c\u0627\u062a \u0627\u0644\u0646\u0627\u0646\u0648\u0633\u0643\u0648\u0628"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/posts\/9121","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/comments?post=9121"}],"version-history":[{"count":5,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/posts\/9121\/revisions"}],"predecessor-version":[{"id":9127,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/posts\/9121\/revisions\/9127"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/media\/9185"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/media?parent=9121"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/categories?post=9121"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ar\/wp-json\/wp\/v2\/tags?post=9121"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}